SMC accepts etanercept (Enbrel®) for restricted use in the treatment of arthritis in children and adolescents

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium (SMC) has accepted etanercept (Enbrel®) for restricted use within NHS Scotland for the treatment of the following:   polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate; psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate; enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy   Its use within these indications is restricted to specialist rheumatology services (including those working within the network for paediatric rheumatology).   The Detailed Advice notes that etanercept has previously been accepted by the SMC for the treatment of ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news